Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL
Status:
Not yet recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
In this study, the investigators are hypothesizing that daratumumab-hyaluronidase will
effectively treat T-ALL in patients who have persistent or recurrent MRD following treatment
with chemotherapy.